Startup Originals Team
Bhopal-based biotech startup StrainX Bioworks has raised $13 million in a funding round co-led by Prime Venture Partners and Leo Capital to expand its alternative protein and bio-manufacturing business. The round also saw participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dholakia Ventures, and WindT Angels.
The funding marks a major milestone for India’s growing synthetic biology and bio-manufacturing ecosystem.
What StrainX Bioworks Does
Founded in 2023 by Akshay Mittal and Alok Malaviya, StrainX Bioworks develops:
- Alternative proteins
- Bio-based ingredients
- Fermentation-driven manufacturing technologies
The startup uses:
- Synthetic biology
- Precision fermentation
- Strain engineering
to create sustainable ingredients for industries such as:
- Food and nutrition
- Healthcare
- Agriculture
- Cosmetics
- Industrial materials
How Synthetic Biology Works
Synthetic biology involves engineering microorganisms like:
- Bacteria
- Yeast
- Fungi
to produce proteins and molecules traditionally sourced from plants or animals.
These microorganisms are then scaled through industrial fermentation systems to manufacture ingredients in controlled environments.
While fermentation technologies have long been used in pharmaceuticals, falling production costs and rising demand for sustainable products are now driving adoption in consumer industries as well.
Funding to Expand Manufacturing and R&D
StrainX said the newly raised capital will be used to:
- Expand research and development operations
- Scale fermentation infrastructure
- Accelerate commercial production in India and overseas markets
The company is also strengthening its Bengaluru research lab while expanding engineering and scientific teams.
The startup currently employs around:
- 100 people
and plans to double its workforce by the end of the financial year.
Scaling Bio-Manufacturing Infrastructure
The startup recently emerged from stealth mode after spending two years building capabilities in:
- Fermentation engineering
- Process scale-up
- Strain development
It currently operates a bio-manufacturing facility in Bhopal with:
- 10,000-litre fermentation capacity
The company plans to increase this capacity nearly tenfold over the next two years as demand grows.
This expansion could position StrainX as one of India’s key players in next-generation bio-manufacturing.
Global Expansion Plans
Apart from India, StrainX is also targeting international markets, including the United States.
The company aims to compete globally in sectors where:
- Sustainable ingredients
- Alternative proteins
- Bio-manufactured products
are seeing rapid demand growth.
The startup believes bio-manufacturing could redefine industrial production over the coming decade.
Founder’s Vision for the Future
Co-founder Akshay Mittal said:
“Bio-manufacturing is going to define the next decade of manufacturing.”
He explained that while the last century was dominated by chemical manufacturing, advances in fermentation engineering and synthetic biology are now making bio-manufacturing:
- More efficient
- More scalable
- Potentially cheaper than traditional methods
This reflects a global shift toward cleaner and more sustainable industrial technologies.
The Bigger Picture
The rise of startups like StrainX highlights how India’s biotech ecosystem is expanding beyond pharmaceuticals into:
- Food-tech
- Sustainable materials
- Climate-focused manufacturing
- Advanced industrial biotechnology
As sustainability becomes a global priority, synthetic biology is emerging as one of the most important deep-tech sectors worldwide.
Conclusion
With $13 million in fresh funding, StrainX Bioworks is positioning itself at the forefront of India’s synthetic biology and alternative protein revolution. By combining fermentation engineering, biotechnology, and sustainable manufacturing, the startup aims to help shape the future of global bio-manufacturing.
